References

pulmo

Пульмонология

PULMONOLOGIYA

0869-01892541-9617

Scientific and Practical Journal “PULMONOLOGIYA” LLC

10.18093/0869-0189-2005-0-4-97-111

pulmo-2100

Research Article

ОБЗОРЫ

REVIEW

Флуимуцил и современная клиническая практика

Fluimucil and recent clinical practice

Чикина

С. Ю.

Chikina

S. Yu.

ФГУ НИИ пульмонологии РосздраваRussian Federation

2005

28082005

0497111

2005

Чикина С.Ю.

Chikina S.Y.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://journal.pulmonology.ru/pulm/article/view/2100

Обзор формально посвящен одному из наиболее "старых" лекарственных средств – ацетилцистеину. Действительно, его клиническое применение охватывает более чем 30-летний период, в котором можно выделить несколько этапов в изучении механизмов его фармакологической активности. Особое внимание к нему было проявлено в связи с поиском антидотов при радиационном воздействии. Ацетилцистеин вошел в список жизненно необходимых лекарственных средств при радиационном поражении человека. Одним из важных этапов в исследовании его механизмов стало применение в области респираторной медицины. Так, исходно ацетилцистеин был предложен как секретолитик, регулирующий образование муцина и стимулирующий его транспорт по дыхательным путям. В последующем была открыта его способность снижать повреждение клеточных структур свободными радикалами. Дисбаланс в системе оксиданты–антиоксиданты играет ведущую патогенетическую роль при таких заболеваниях, как хроническая обструктивная болезнь легких (ХОБЛ), респираторный дистресс-синдром и некоторых других. Необходимо подчеркнуть, что ацетилцистеин с успехом применяется при инфекционных заболеваниях как верхних, так и нижних отделов дыхательных путей. Значительный прогресс был достигнут и при таких прогностически неблагоприятных заболеваниях, какими является разнообразная группа интерстициальных заболеваний легких. Современный этап клинического применения охватил такие области как кардиология, диабетология, химиотерапия, трансплантация органов и тканей, токсикология и некоторые другие. Читатель найдет в обзоре С.Ю.Чикиной новую информацию, которая позволит прийти к выводу о том, что ацетилцистеин, начиная с 70-х гг. прошлого столетия, всегда остается современным лекарственным средством. Академик РАМН профессор А.Г.Чучалин

References1

Webb W. Clinical evaluation of a new mucolytic agent acetylcysteine. J. Thorac. Cardiovasc. Surg. 1962; 44: 330–343.

Reas H. The effect of N-acetylcysteine on the viscosity of tracheobronchial secretion in cystic fibrosis of the pancreas. J. Pediatr. 1963; 62: 31–35.

De Vries N., De Flora S. N-acetylcysteine. J. Cell Biochem. 1993; suppl. 17F: 270–278.

Prescott L.F., Park J., Ballantyne A. et al. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet 1977; 2: 432–434.

Prescott L.F., Illingworth R.N., Critchley J.A. et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisning. Br. Med. J. 1979; 2: 1097–1100.

Bonanomi L., Gazzaniga A. Toxicological, pharmacokinetic and metabolic studies of acetylcysteine. Eur. J. Respir. Dis. 1980; 61 (suppl. III): 45–51.

De Flora S., Izzotti A., D'Agostini F., Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am. J. Med. 1991; 91 (3C): 122S–130S.

De Flora S., Cesarone C.F., Balansy R.M. et al. Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J. Cell Biochem. 1995; 22 (suppl.): 33–41.

De Flora S., Astengo M., Serra D., Bennicelli S. Inhibition of urethan-induced lung tumours in mice by dietary N-acetylcysteine. Cancer Lett. 1986; 32: 235–241.

Rogers D.F., Jeffery P.K. Inhibition by oral N-acetylcysteine of cigarette smoke-induced "bronchitis" in the rat. Exp. Lung Res. 1986; 10: 267–283.

Moldeus P., Cotgreave I.A., Berddren M. Lung protection by a thiol-containing antioxidant N-acetylcysteine. Respiration 1986; 50: 31–42.

De Flora S., Bennicelli C., Zanacchi P. et al. In vitro effects of N-acetylcysteine on the mutagenicity of direct-acting compounds and procarcinogens. Carcinogenesis (Lond.) 1984; 5: 505–510.

Hochstein P., Atallah A.S. The nature of oxidants and antioxidant systems in the inhibition of mutation and cancer. Mutat. Res. 1988; 202: 363–375.

Rouse B.T., Horohov D.W. Immunosuppression in viral infections. Rev. Infect. Dis. 1986; 8: 850–873.

Maeda H., Akaike T. Oxygen-free radicals as pathogenic molecules in viral diseases. Proc. Soc. Exp. Biol. (N.Y.) 1991; 198: 721–727.

De Flora S., Grassi C., Carati L. Attenuation of influenzalike symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur. Respir. J. 1997; 10: 1535–1541.

Peristeris P., Clark B.D., Gatti S. et al. N-acetylcysteine and glutathione as inhibitors of tumor necrosis factor production. Cell. Immunol. 1992; 140: 390–399.

Murray C.J.L., Lopez A.D. Evidence-based health policy — lessons from the Global Burden of Disease Study. Science 1996; 274: 740–743.

World Health Organization. World health report. Geneva: World Health Organization; 2000.

MacNee W. Oxidant / antioxidants and COPD. Chest 2000; 117: 303S–317S.

Kharitonov S.A., Barnes P.J. Exhaled markers of pulmonary diseases. Am. J. Respir. Crit. Care Med. 2001; 163: 1693–1722.

Tattersall A.B., Bridgman K.M., Huitson A. Acetylcysteine (Fabrol) in chronic bronchitis — a study in general practice. J. Intern. Med. Res. 1983; 11: 279–284.

Stey C., Steurer J., Bachmann S. et al. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur. Respir. J. 2000; 16: 253–262.

Watson J.H.L., Brinkman G.L. Electron microscopy of the epithelial cells of normal and bronchitic human bronchus. Am. Rev. Respir. Dis. 1964; 90 (6): 851–855.

Salvato G. Some histological changes in chronic bronchitis and asthma. Thorax 1968; 23: 168–172.

Mullen B.J., Wright J.L., Wiggs B.R. et al. Structure of central airway in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax 1987; 42: 843–848.

Riise G.C., Larsson S., Larsson P. et al. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy. Eur. Respir. J. 1994; 7: 94–101.

Rasmussen J.B., Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled release tablets in patients with chronic bronchitis. Eur. Respir. J. 1988; 1: 351–355.

Grandjean E.M., Berthet P.H., Ruffnman R., Leuenberger P.H. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol. Res. 2000; 42 (1): 39–50.

Grandjean E.M., Berthet P., Ruffnman R., Leuenberger P. Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: a meta-analysis of published double-blind, placebo-controlled clinical trials. Clin. Ther. 2000; 22 (2): 209–221.

Poole P.J., Black P.N. Oral mucolytic drugs for exacerbations of chronic obstructive pulmonary disease: systematic review. Br. Med. J. 2001; 322: 1–6.

Gerrits C.M.J.M., Herings R.M.C., Leufkens H.G.M., Lammers J.-W.J. N-acetylcysteine reduces the risk of rehospitalizations among patients with chronic obstructive pulmonary disease. Eur. Respir. J. 2003; 21: 795–798.

Decramer M., Rutten-van Molken M., Dekhuijzen P.N. et al. Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (9470): 1552 — 1560.

Belman M.J., Batnick W.C., Shin J.W. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 153: 967–975.

Tantucci C., Duguet A., Similowski T. et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur. Respir. J. 1998; 12: 799–804.

Duranti R., Filippelli M., Bianchi R. et al. Inspiratory capacity and decrease in lung hyperinflation with albuterol in COPD. Chest 2002; 122: 2009–2014.

Hansen N.C., Skriver A., Brorsen-Riis L. et al. Orally administered N-acetylcysteine may improve general wellbeing in patients with mild chronic bronchitis. Respir. Med. 1994; 88 (7): 531–535.

Sen C.K., Atalay M., Hanninen O. Exercise-induced oxidative stress: glutatione supplementation and deficiency. J. Appl. Physiol. 1994; 77 (5): 2177–2187.

Vassilakopouolos T., Karatsa M.-H., Latsaounou P. et al. Antioxidants attenuate the plasma cytokine response to exercise in humans. J. Appl. Physiol. 2003; 94: 1025–1032.

Reid M.B., Stokic S., Koch S.M. et al. N-acetylcysteine inhibits muscle fatigue in humans. J. Clin. Invest. 1994; 94: 2468–2474.

Medved I., Brown M.J., Bjorksen A.R. et al. N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans. J. Appl. Physiol. 2003; 94: 1572–1582.

Medved I., Brown M.J., Bjorksten A.R., McKenna M.J. Effects if intravenous N-acetylcysteine infusion on time fatigue and potassium regulation during prolonged cycling exercise. J. Appl. Physiol. 2004; 96: 211–217.

Medved I., Brown M.J., Bjorksen A.R. et al. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J. Appl. Physiol. 2004; 97: 1477–1485.

Travaline J.M., Sudarshan S., Roy B.G. et al. Effect of N-acetylcysteine on human diaphragm strength and fatigability. Am. J. Respir. Crit. Care Med. 1997; 156: 1567–1571.

Polkey M.I., Kyroussis D., Hamnegard C.H. et al. Diaphragm strength in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1996; 154: 1310–1317.

Gosselink R., Troosters T., Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am. J. Respir. Crit. Care Med. 1996; 153: 976–980.

Bernard S., LeBlanc P., Whittom F. et al. Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1998; 158: 629–634.

Couillard A., Maltais F., Saey D. et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2003; 167: 1664–1669.

Koechlin C., Couillard A., Simar D. et al. Does oxidative stress alter quadriceps endurabce in chronic obstructive pulmonary disease? Am. J. Respir. Crit. Care Med. 2004; 169: 1022–1027.

Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am. J. Respir. Crit. Care Med. 2000; 161: 646–664.

Hamman L., Rich A.R. Fulminating diffuse interstitial fibrosis of the lungs. Trans. Am. Clin. Climatol. Assoc. 1935; 51: 154–163.

Beeh K.M., Beier J., Haas I.C. et al. Glutathione deficiency of the lower respiratory tract in patients with idiopathic pulmonary fibrosis. Eur. Respir. J. 2002; 19: 1119–1123.

Behr J., Degenkolb B., Krombach F., Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur. Respir. J. 2002; 19: 906–911.

Meyer A., Buhl R., Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur. Respir. J. 1994; 7: 431–436.

Meyer A., Buhl R., Kampf S., Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am. J. Respir. Crit. Care Med. 1995; 152 (3): 1055–1060.

Benr J., Maier K., Degenkolb B. et al. Antioxidant and clinical effects og high-dose N-acetylcysteine in fibrosing alveolitis. Am. J. Respir. Crit. Care Med. 1997; 156: 1897–1901.

Demedts M.G.P., Nicholson A.G., Verbeken E.K. et al. Ifigenia-study on N-acetylcysteine in idiopathic pulmonary fibrosis (IPF): comparison of HRCT and lung biopsy. Eur. Respir. J. 2001; 18 (suppl. 33): 527s.

Demedts M., Thomeer M., Verschakelen J. et al. IFIGENIA-study: methods, patient characteristics and diagnostic confirmation by independent HRCT and histology committees. Eur. Respir. J. 2002; 20 (suppl. 38): 588s.

Thomeer M., Demedts M., Behr J. et al. Survival in idiopathic pulmonary fibrosis: results of the IFIGENIA follow up study. Eur. Respir. J. 2004; 24 (suppl. 48): 254s.

Demedts M., Behr J., Buhl R. et al. IFIGENIA-study in IPF: effects of N-acetylcysteine (NAC) on CRP, dyspnea, exercise test and HRCT. Eur. Respir. J. 2004; 24 (suppl. 48): 668s.

Demedts M., Behr J., Buhl R. et al. IFIGENIA: effects of N-acetylcysteine (NAC) on primary end points VC and Dlco. Eur. Respir. J. 2004; 24 (suppl. 48): 668s.

Behr J., Demedts M., Buhl R. et al. IFIGENIA (Idiopathic pulmonary Fibrosis International Group Exploring NAC I Annual): effects of N-acetylcysteine (NAC) on lung function and gas exchange in IPF patients. Eur. Respir. J. 2004; 24 (suppl. 48): 668s.

National Institutes of Health (NIH) / National Heart, Lung, Blood Institute. Facts about cystic fibrosis. Bethesda, MD, U.S. Dept of Health and Human Services; 1995. NIH Publication No. 95–3650.

Bedrossian C.W., Greenberg S.D., Singer D.B. et al. The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups. Hum. Pathol. 1976; 7: 195–204.

Sheppard M.N. The pathology of cystic fibrosis. In: Hodson M.E., Geddes D.M., eds. Cystic fibrosis. London: Chapman & Hall Medical; 1997. 13–22.

Ratjen F., Wonne R., Posselt H.G. et al. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur. J. Pediatr. 1985; 144 (4): 374–378.

Stafanger G., Garne S., Howitz P. et al. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur. Respir. J. 1988; 1 (2): 161–167.

Stafanger G., Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur. Respir. J. 1989; 2: 234–237.

Maayan C., Bar-Yishay E., Yaacobi T. et al. Immediate effect of various treatment on lung function in infants with cystic fibrosis. Respiration 1989; 55 (3): 144–151.

Laurent T., Markett M., Feihi F. et al. Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Chest 1996; 109 (1): 163–166.

Pepe P.E. Clinical entity of adult respiratory distress syndrome: definition. prediction, and prognosis. Crit. Care Clin. 1986; 2: 377–403.

Repine J.E., Parsons P.E. Oxidant-antioxidant balance in endotoxin-induced oxidative injury and tolerance to oxidative injury. In: Brigham K.L., ed. Endotoxin and the lung. New York: Marcel Dekker; 1994. 207–227.

Bernard G.R., Lucht W.D., Niedermeyer M.E. et al. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J. Clin. Invest. 1984; 73: 1772–1784.

Jepsen S., Herlevsen P., Knudsen P. et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit. Care Med. 1992; 20 (7): 918–923.

Suter P.M., Domenighetti G., Schaller M.D. et al. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest 1994; 105: 190–194.

Spies C.D., Reinhart K., Witt I. et al. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit. Care Med. 1994; 22 (11): 1738–1746.

Domenighetti G., Suter P.M., Schaller M.D. et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J. Crit. Care 1997; 12 (4): 177–182.

Del Sorbo L., Zhang H. Is there a place for N-acetylcysteine in the treatment of septic shock? Crit. Care 2004; 8 (2): 93–95.

Bergstrand H., Bjornson A., Eklung A. et al. Stimuliinduced superoxide radical generation in vitro by human alveolar macrophages from smokers: modulation by N-acetylcysteine treatment in vitro. J. Free Radic. Biol. Med. 1986; 2: 119–127.

Linden M., Wieslander E., Eklund A. et al. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur. Respir. J. 1988; 1: 645–650.

Eklund A., Erikkson O., Hakansson L. et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur. Respir. J. 1988; 1: 832–838.

Schooten F.J.V., Nia A.B., De Flora S. et al. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol., Biomarkers Prev. 2002; 11: 167–175.

van Zandwijk N., Dalesio O., Pastorino U. et al. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. J. Nat. Cancer Inst. 2000; 92 (120): 977–986.

Potter J.D., Bigler J., Fosdick L. et al. Colorectal adenomatous and hyperplastic polyps: smoking and N-acetyltransferase 2 polymorphisms. Cancer Epidemiol. Biomarkers Prev. 1999; 8: 69–75.

Heineman E.F., Zham S.H., McLaughlin J.K., Vaught J.B. Increased risk of colorectal cancer among smokers: results of a 26-year follow-up of US veterans and a review. Int. J. Cancer 1994; 59: 728–738.

Greenwald P., Kelloff G.J., Boone C.W., McDonald S.S. Genetic and cellular changes in colorectal cancer: proposed targets of chemopreventive agents. Cancer Epidemiol. Biomarkers Prev. 1995; 4: 691–702.

Ponz de Leon M., Roncucci L. Chemoprevention of colorectal tumors: role of lactulose and of other agents. Scand. J. Gastroenterol. 1997; 222: 72–75.

Estensen R.D., Levy M., Klopp S.J. et al. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett. 1999; 147: 109–114.

Fishbane S., Durham J.H., Marzo K., Rudnick M. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. J. Am. Soc. Nephrol. 2004; 15: 251–260.

Zager R.A., Johnson A.C., Hanson S.Y. Radiographic contrast media-induced tubular injury: evaluation of oxidant stress and plasma membrane integrity. Kidney Int. 2003; 64: 128–139.

Tepel M., van der Giet M., Schwarzfeld C. et al. Prevention of radiographic-contrast-agent-induced reductrions in renal function by acetylcysteine. N. Engl. J. Med. 2000; 343 (3): 180–184.

Durham J.D., Caputo C., Dokko J. et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002; 62: 2202–2207.

Weisberg I.S., Kurnik P.B., Kurnik B.R. Risk of radiocontrast nephropathy in patiehts with and without diabetes mellitus. Kidney Int. 1994; 45 (1): 259–265.

Kay J., Chow W.H., Chan T.M. et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiographt and intervention: a randomized controlled trial. J.A.M.A. 2003; 289: 553–558.

Shyu K.G., Cheng J.J., Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J. Am. Coll. Cardiol. 2002; 40: 1383–1388.

Diaz-Sandonal L.J., Kosowsky B.D., Losordo D.W. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am. J. Cardiol. 2002; 89: 356–358.

Baker C.S., Wragg A., Kumar S. et al. A rapid protocol for the prevention of contrast-induced renal dysfunction: The RAPPID study. J. Am. Coll. Cardiol. 2003; 41: 2114–2118.

Allaqaband S., Tumuluri R., Malik A.M. et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radio contrast-induced nephropathy. Catheter. Cardiovasc. Interv. 2002; 57: 279–283.

Boccaladnro F., Amhad M., Smalling P.W., Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter. Cardiovasc. Interv. 2003; 58: 336–341.

100

Briguori C., Manganelli F., Scarpato P. et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J. Am. Coll. Cardiol. 2002; 40: 298–303.

101

Goldenberg I., Jones M., Metetzki S. et al. Contrast-associated nephropathy and clinical outcome of patients with chronic renal insufficiency undergoing cardiac catheterization: lack of additive benefit of acetylcysteine to saline hydration. J. Am. Coll. Cardiol. 2003; 41: 537A.

102

Loutrianakis E., Stella D., Hussain A. et al. Randomized comparison of fenaldopam and N-acetylcysteine to saline in the prevention of radiocontrast nephropathy. J. Am. Coll. Cardiol. 2003; 41: 327A.

103

Oldemeyer J.B., Cichowski E.K., Wurdeman R.L. et al. Prophylactic acetylcysteine is not effective in preventing contrast-induced nephropathy following coronary angiography. Am. Heart J. 2003; 146: E23.

104

Vallero A., Cesano G., Pozzato M. et al. Contrast nephropathy in cardiac procedures: no advantages with prophylactic use of N-acetylcysteine (NAC). G. Ital. Nefrol. 2002; 19: 529–533.

105

Brick R., Krzossok S., Markowetz F. et al. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598–603.

106

Ignatto L. Endothelium-derived nitric oxide: pharmacology and relationship to the actions of organic esters. Pharmacol. Res. 1989; 6: 651–659.

107

Ardissino D., Merlini P.A., Savonitto S. et al. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J. Am. Coll. Cardiol. 1997; 29 (5): 941–947.

108

Boesgaard S., Aldershvile J., Poulsen H.E. Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris. Circulation 1992; 85 (1): 143–149.

109

Andrews N.P., Prasad A., Quyyumi A.A. N-acetylcysteine improves coronary and peripheral vascular function. J. Am. Coll. Cardiol. 2001; 37 (1): 117–123.

110

Horowitz J.D., Antman E.M., Lorell B.H. et al. Potentiation of cardiovascular effects of nitroglycerin by N-acetylcysteine. Circulation 1983; 68 (8): 1247–1253.

111

Parker J.O., Farrell B., Lahey K.A., Rose B.F. Nitrate tolerance: the lack of effect of N-acetylcysteine. Circulation 1987; 76 (3): 572–576.

112

Winniford M.D., Kennedy P.L., Wells P.J., Hills L.D. Potentiation of nitroglycerin-induced coronary dilatation by N-acetylcysteine. Circulation 1986; 73 (1): 138–142.

113

Sochman J., Vrbska J., Musilova B., Pocek M. Infarct size limitation: acute N-acetylcysteine defemse (ISLAND trial): preliminary analysis and report after the first 30 patients. Clin. Сardiol. 1996; 19 (2): 94–100.

114

Litovitz T.L., Klein-Schwartz W., White S. et al. 2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am. J. Emerg. Med. 2001; 19: 337–395.

115

Moklesi B., Leikin J.B., Murray P., Corbridge T.C. Adult toxicology in critical care. Part II: specific poisoning. Chest 2003; 123: 897–922.

116

Smilkstein M.J., Knapp G.L., Kulig K.W. et al. Efficacy of oral N-acetylcysteine in the treatment of accetaminophen overdose: analysis of the national multicenter study (1976–1985). N. Engl. J. Мed. 1988; 319: 1557–1562.

117

Harrison P.M., Keays R., Bray G.P. et al. Improves outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet 1990; 335: 1572–1573.

118

Makin A.J., Wendon J., Williams R. A 7-year experience of severe acetaminophen-induced hepatoxity (1987–1993). Gastroenterology. 1995; 109 (6): 1907–1916.

119

Kelly D.A. Managing liver failure. Postgrad. Med. J. 2002; 78: 660–667.

120

Woo O.F., Mueller P.D., Olson K.R. et al. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann. Emerg. Med. 2000; 35: 363–368.

121

Wallace C.I., Dargan P.I., Jones A.L. Paracetamol poisoning: an evidence-based flowchart to guide management. Emerg. J. Med. 2002; 19: 202–205.

122

Smilkstein M.J., Bronstein A.C., Linden C. et al. Acetaminophen overdose: a 48-h intravenous N-acetylcysteine treatment protocol. Ann. Emerg. Med. 1991; 20: 1058–1063.

123

Buckley N.A., Whyte I.M., O'Connel D.L. et al. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J. Toxicol. Clin. Toxicol. 1999; 37 (6): 759–767.

124

Weiss L., Hilst E., Hofschneider P.H. Anti-hepatitis B virus activity of N-acetylcysteine, new aspect a well established drug. Antiviral Res. 1996; 32: 43–53.

125

Bova P., de la Pena A., Beloqui O. et al. Antioxidant status and glutathione metabolism in peripheral blood mononuclear cells from patients with chronic hepatitis C. J. Hepatol. 1999; 31 (5): 808–814.

126

Larrea E., Beloqui O., Munoz-Navas M.A. et al. Superoxide dismutase in patients with chronic hepatitis C virus infection. Free Radic. Biol. Med. 1998; 24 (7–8): 1235–1241.

127

Neri S., Ierna D., Antoci S. et al. Association of alphainterferon and acetyl cysteine in patients with chronic C hepatitis. Panminerva Med. 2000 42 (3): 187–192.

128

Beloqui O., Prieto J., Suarez M. et al. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis C: a pilot study. J. Interferon Res. 1993; 13 (4): 279–282.

129

Cimino L., Belisario M.A., Intrieri M. et al. Effect of N-acetylcysteine on lymphomonocyte glutathione and response to interferon treatment in C-virus chronic hepatitis. Ital. J. Gastroenterol. Hepatol. 1998; 30 (2): 189–193.

130

Weidenbach H., Arth M., Adler G. et al. Treatment of chronic hepatitis B with high-dose intravenous N-acetyl-L-cysteine. Hepatogastroenterology 2003; 50 (54): 2105–2108.

131

Ideo G., Bellobuono A., Tempini S. et al. Antioxidant drugs combined with alpha-interferon in chronic hepatitis C not responsive to alpha-interferon alone: a randomized, multicentre study. Eur. J. Gastroenterol. Hepatol. 1999; 11 (11): 1203–1207.

132

Gunduz H., Karabay O., Tamer A. et al. N-acetyl cysteine therapy in acute viral hepatitis. Wld J. Gastroenterol. 2003; 9 (12): 2698–2700.

133

Herzenberg L.A., De Rosa S.C., Dubs J.G. et al. Glutathione deficiency is associated with impaired survival in HIV disease. Proc. Natl. Acad. Sci. U S A 1997; 94: 1967–1972.

134

Malorni W., Rivabene R., Lucia B.M. et al. The role of oxidative imbalance in progression of AIDS: effect of the thiol supplier N-acetylcysteine. AIDS Res. Hum. Retrovirus. 1998; 14 (7): 1589–1596.

135

Droge W., Breitkreutz R. Glutathione and immune function. Proc. Nutr. Soc. 2000; 59 (4): 595–600.

136

Nakamura H., Masutani H., Yodoi J. Redox imbalance and its control in HIV infection. Antioxid. Redox Signal. 2002; 4 (3): 455–464.

137

Baruchei S., Wainberg M.A. The role of oxidative stress in disease progression in individuals infected by the human immunodeficiency virus. J. Leukocyte Biol. 1992; 52 (1): 111–114.

138

Breitkreutz R., Pittack N., Nebe C.T. et al. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J. Mol. Med. 2000; 78 (1): 55–62.

139

Lopez O., Bonnefoni-Rousselot D., Edeas M. et al. Could antioxidant supplementation reduce antiretroviral therapy-induced chronic stable hyperlactatemia? Biomed and Pharmacother. 2003; 57 (3–4): 113–116.

140

De Rosa S.C., Zaretsky M.D., Dubs J.G. et al. N-acetylcysteine replenishes glutathione in HIV infection. Eur. J. Clin. Invest. 2000; 30 (10): 915–920.

141

James J.S. Stanford NAC study: glutathione level predicts survival. AIDS Treat. News 1997; 7 (266): 1–5.

The authors declare that there are no conflicts of interest present.